drugset / Trial / NCT02956551
Personalized DC Vaccine for Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.
Timeline
- Start
- 2016-11-30
- Primary completion
- 2019-12-31
- Completion
- 2020-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC vaccine | Vaccine | — | Subcutaneous |